ENO3

Across TCGA pan-cancer cohorts, ENO3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ENO3 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ENO3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ENO3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where ENO3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.886	1.000	.019	14	view →
HNSC	DFS	Tertile	III,IV	0.911	0.641	.009	13	view →
PDAC	DFS	Quartile	III,IV	0.195	0.719	.010	12	view →
CCRCC	DFS	Median	All	0.908	0.723	.005	11	view →
LSCC	OS	Quartile	III,IV	0.558	1.000	.021	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ENO3–LUAD (OS)

Open the LUAD breakdown →